Valuation: Orthocell Limited

Market Cap 230M 160M 140M 129M 119M 226M 15.26B 1.54B 606M 7.52B 601M 588M 25.85B P/E 2026 *
-21.1x
P/E 2027 * -42.3x
Enterprise Value 187M 130M 114M 105M 97.08M 184M 12.43B 1.26B 493M 6.12B 489M 479M 21.04B EV / Sales 2026 *
14.9x
EV / Sales 2027 * 8.55x
Free-Float
83.36%
Yield 2026 *
-
Yield 2027 * -
1 day+1.20%
1 week+11.92%
Current month+16.55%
1 month+13.42%
3 months+3.05%
6 months-21.76%
Current year-22.12%
1 week 0.76
Extreme 0.76
0.9
1 month 0.7
Extreme 0.7
0.9
Current year 0.7
Extreme 0.7
1.16
1 year 0.7
Extreme 0.7
1.6
3 years 0.32
Extreme 0.322
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 21/03/2006
Chief Executive Officer 60 21/03/2006
Director of Finance/CFO - 01/08/2025
Director TitleAgeSince
Director/Board Member 60 21/03/2006
Director/Board Member 60 08/03/2023
Chairman - 01/06/2023
Date Insider Type Main position Quantity % Market Cap.
03/05Buy 23,615 0.0087%
01/05Buy

Chairman

25,000 0.0092%
25/02Buy

Chairman

32,500 0.0120%
Change 5-day change 1-year change 3-year change Capi.($)
+1.20%+11.92%-33.20%+144.93% 160M
+0.45%+0.69%+21.20%+1.50% 196B
-1.16%-4.51%-20.56%+19.96% 144B
+1.57%+0.57%-2.83%-16.25% 141B
-0.49%-0.82%-56.62%-14.64% 66.54B
+0.96%-2.29%+18.14%-0.25% 53.09B
+0.61%-1.09%-24.93%-30.81% 44.12B
+0.52%+2.75%+8.93%+13.34% 37.93B
-0.19%-0.75%+6.66%+42.84% 36.96B
0.00%-1.32%-13.88%-20.38% 29.43B
Average +0.35%+0.44%-9.71%+14.02% 74.91B
Weighted average by Cap. +0.27%-0.96%-3.93%+0.06%

Financials

2026 *2027 *
Net sales 12.55M 8.73M 7.64M 7.04M 6.5M 12.34M 833M 84.15M 33.05M 410M 32.78M 32.06M 1.41B 23.55M 16.38M 14.33M 13.22M 12.21M 23.16M 1.56B 158M 62.01M 770M 61.5M 60.16M 2.65B
Net income -12.5M -8.69M -7.61M -7.01M -6.48M -12.29M -829M -83.81M -32.91M -409M -32.65M -31.93M -1.4B -7.85M -5.46M -4.78M -4.41M -4.07M -7.72M -521M -52.63M -20.67M -257M -20.5M -20.05M -882M
Net Debt -42.75M -29.73M -26.01M -23.99M -22.16M -42.04M -2.84B -287M -113M -1.4B -112M -109M -4.8B -28.75M -20M -17.49M -16.13M -14.9M -28.27M -1.91B -193M -75.7M -940M -75.08M -73.45M -3.23B
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
10/07/26 $0.8450 +1.20% 152,909
09/07/26 $0.8350 -1.18% 176,438
08/07/26 $0.8450 -2.87% 293,046
07/07/26 $0.8700 +4.82% 852,234
06/07/26 $0.8300 +9.93% 696,934
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8450AUD
Average target price
1.250AUD
Spread / Average Target
+47.93%

Quarterly revenue - Rate of surprise